Assessing the in vivo efficacy of biologic antiangiogenic therapies Peter M. WilsonMelissa J. LaBonteHeinz-Josef Lenz Review Article 09 October 2012 Pages: 1 - 12
Therapeutic potential of targeting ceramide/glucosylceramide pathway in cancer Melis Kartal YandımElif ApohanYusuf Baran Review Article 17 October 2012 Pages: 13 - 20
A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound, administered as a 24-h continuous infusion in patients with advanced solid tumors Michael S. GordonRobert Ilaria Jr.Patricia M. LoRusso Original Article 11 December 2012 Pages: 21 - 27
Phase I study of bevacizumab combined with irinotecan and S-1 as second-line chemotherapy in patients with advanced colorectal cancer Hitoshi KusabaTaito EsakiEishi Baba Original Article 11 December 2012 Pages: 29 - 34
Pharmacokinetic study of omacetaxine mepesuccinate administered subcutaneously to patients with advanced solid and hematologic tumors John NemunaitisAlain MitaAdam Craig Original Article Open access 04 October 2012 Pages: 35 - 41
Two-year adjuvant imatinib mesylate after complete resection of localized, high-risk GIST with KIT exon 11 mutation Yoon-Koo KangByung Woog KangMin-Hee Ryu Original Article 07 October 2012 Pages: 43 - 51
Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023 Bojana Milojkovic KerklaanVeronique DiérasAhmad Awada Original Article 29 September 2012 Pages: 53 - 62
Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor–positive metastatic breast cancer Francisco J. EstevaStacy L. MoulderSai-Ching Yeung Original Article 28 September 2012 Pages: 63 - 72
Formation of active products of benzaldehyde dimethane sulfonate (NSC 281612, DMS612) in human blood and plasma and their activity against renal cell carcinoma lines Robert A. PariseBean N. AnyangJan H. Beumer Original Article 05 October 2012 Pages: 73 - 83
Uridine diphosphate glucuronosyl transferase 1 family polypeptide A1 gene (UGT1A1) polymorphisms are associated with toxicity and efficacy in irinotecan monotherapy for refractory pancreatic cancer Naminatsu TakaharaYousuke NakaiKazuhiko Koike Original Article 29 September 2012 Pages: 85 - 92
A Phase I study of pazopanib in combination with gemcitabine in patients with advanced solid tumors Ruth PlummerAyman MadiMax E. Scheulen Original Article Open access 11 October 2012 Pages: 93 - 101
Vinorelbine and capecitabine in anthracycline- and/or taxane-pretreated metastatic breast cancer: sequential or combinational? Jian ZhangShi-Yang GuXi-Chun Hu Original Article 02 October 2012 Pages: 103 - 113
Phase I study of 5-aza-2′-deoxycytidine in combination with valproic acid in non-small-cell lung cancer B. F. ChuM. J. KarpenkoG. A. Otterson Original Article 09 October 2012 Pages: 115 - 121
Evaluation of the pharmacokinetics and safety of bosutinib in patients with chronic hepatic impairment and matched healthy subjects Richat AbbasStephan ChalonDaryl Sonnichsen Original Article 30 September 2012 Pages: 123 - 132
PK-PD modeling of combination efficacy effect from administration of the MEK inhibitor GDC-0973 and PI3K inhibitor GDC-0941 in A2058 xenografts Edna F. ChooChee M. NgLaurent Salphati Original Article 07 October 2012 Pages: 133 - 143
Combination of low-dose docetaxel and standard-dose S-1 for the treatment of advanced gastric cancer: efficacy, toxicity, and potential predictive factor Yuehong CuiQian LiTianshu Liu Original Article 12 October 2012 Pages: 145 - 152
Changing the expression vector of multidrug resistance genes is related to neoadjuvant chemotherapy response Nicolay V. LitviakovNadezhda V. CherdyntsevaVladimir M. Perelmuter Original Article 02 October 2012 Pages: 153 - 163
Combination treatment of localized concurrent chemoradiation therapy and transarterial chemoembolization in locally advanced hepatocellular carcinoma with intrahepatic metastasis Mi Sung ParkSeung Up KimJinsil Seong Original Article 19 October 2012 Pages: 165 - 173
Effects of tumor type, degree of obesity, and chemotherapy regimen on chemotherapy dose intensity in obese cancer patients T. MiyaharaS. MochinagaH. Fujito Original Article 12 October 2012 Pages: 175 - 182
Oblimersen in combination with temozolomide and albumin-bound paclitaxel in patients with advanced melanoma: a phase I trial Patrick A. OttJason ChangAnna C. Pavlick Original Article 12 October 2012 Pages: 183 - 191
Co-administration of vismodegib with rosiglitazone or combined oral contraceptive in patients with locally advanced or metastatic solid tumors: a pharmacokinetic assessment of drug–drug interaction potential Patricia M. LoRussoSarina A. Piha-PaulRichard A. Graham Original Article 11 October 2012 Pages: 193 - 202
Erlotinib in patients with advanced lung squamous cell carcinoma Chi-Lu ChiangChun-Ming TsaiYu-Chin Lee Original Article 10 October 2012 Pages: 203 - 208
Pharmacokinetic–pharmacodynamic relationship of bosutinib in patients with chronic phase chronic myeloid leukemia Poe-Hirr HsyuDiane R. MouldMichael Amantea Original Article 16 October 2012 Pages: 209 - 218
Effects of famotidine or an antacid preparation on the pharmacokinetics of nilotinib in healthy volunteers Ophelia Q. P. YinVéronique BédouchaSteven Novick Original Article 16 October 2012 Pages: 219 - 226
Phase 1 study of trebananib (AMG 386), an angiogenesis targeting angiopoietin-1/2 antagonist, in Japanese patients with advanced solid tumors Toshihiko DoiAtsushi OhtsuDavid M. Weinreich Original Article Open access 03 November 2012 Pages: 227 - 235
Effect of abiraterone acetate plus prednisone on the pharmacokinetics of dextromethorphan and theophylline in patients with metastatic castration-resistant prostate cancer K. N. ChiA. TolcherM. Acharya Original Article 12 October 2012 Pages: 237 - 244
Prognostic significance of RACGAP1 mRNA expression in high-risk early breast cancer: a study in primary tumors of breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trial K. PliarchopoulouK. T. KalogerasG. Fountzilas Original Article 25 October 2012 Pages: 245 - 255
XELOX and bevacizumab followed by single-agent bevacizumab as maintenance therapy as first-line treatment in elderly patients with advanced colorectal cancer: the boxe study Gerardo RosatiAntonio AvalloneDomenico Bilancia Original Article 26 October 2012 Pages: 257 - 264
Association between KRAS codon 13 mutations and clinical response to anti-EGFR treatment in patients with metastatic colorectal cancer: results from a meta-analysis Jian ChenYun YeGenming Shi Original Article 23 October 2012 Pages: 265 - 272
Hemodialysis no reason to withhold everolimus J. M. van RooijenE. G. E. de Vries Letter to the Editor 08 November 2012 Pages: 273 - 274